comprehensive -WSS

comprehensive

author：explore 2025-10-01 23:03:53 - browse：38369

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： FDA approves RSV monoclonal antibody for infants, toddlers

WSS

After John Oliver segment, STAT readers share their opioid

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Some of the ways extreme heat will change life as we know it

Where are patients getting their prescriptions for GLP

Listen: Your guide to Wegovy's blockbuster heart study

An innovative path out of biotech’s “valley of death”

explore

comprehensive

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Hollywood unions extend contract negotiations for actors

Why hospitals are withdrawing from US News rankings

The high cost of giving birth even with insurance

Startup Neumora takes a novel depression drug to Phase 3

Walensky prepares to leave CDC — and Congress — behind

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

The high cost of giving birth even with insurance

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

explore

At Orexo, a ‘turning point’ for everything but digital health

WHO calls for emergency meeting on new China virus, as cases spread

Cosmetics set for new safety regulation. Why the industry is on board

An innovative path out of biotech’s “valley of death”

AI can’t replace a physician’s gut feeling

STAT Virtual Event: The State of Biosimilars: What to Watch

hotspot

hotspot

leisure time

knowledge